secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verve Therapeutics, Inc. (—)
CIK:        0001840574
Form:       8-K
Filed at:   2023-02-17T23:59:59+00:00
Accession:  0001193125-23-041486
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verve Therapeutics amends bylaws to align with universal proxy rules
--------------------------------------------------------------------

- Board approved Second Amended and Restated Bylaws effective February 14, 2023.
- Eliminates requirement to provide stockholder list during meetings; adds adjournment for technical failures.
- Enhances nomination procedures: requires disclosure and 67% voting power solicitation under Rule 14a-19.
- Non-compliant nominations will be disregarded; proxies or votes for such nominees not counted.
- Includes technical, conforming, and clarifying changes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840574/000119312523041486/0001193125-23-041486-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840574/000119312523041486/d447068d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-041486

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer